Published in J Immunol on November 01, 1997
Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med (1999) 2.76
Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). Biochem J (2000) 2.29
Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio (2013) 1.62
Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput Biol (2007) 1.29
HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther (2007) 1.22
Neuronal brain-derived neurotrophic factor is synthesized in excess, with levels regulated by sortilin-mediated trafficking and lysosomal degradation. J Biol Chem (2011) 1.09
Differential modulation of surface and intracellular protein expression by T cells after stimulation in the presence of monensin or brefeldin A. Clin Diagn Lab Immunol (2002) 1.07
Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol (2012) 1.07
Identification of key processes that control tumor necrosis factor availability in a tuberculosis granuloma. PLoS Comput Biol (2010) 1.00
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol (2000) 0.97
NF-κB Signaling Dynamics Play a Key Role in Infection Control in Tuberculosis. Front Physiol (2012) 0.96
Studies on the role of acid sphingomyelinase and ceramide in the regulation of tumor necrosis factor alpha (TNFalpha)-converting enzyme activity and TNFalpha secretion in macrophages. J Biol Chem (2010) 0.95
Biology of TACE inhibition. Ann Rheum Dis (2001) 0.93
Calcineurin and vacuolar-type H+-ATPase modulate macrophage effector functions. Proc Natl Acad Sci U S A (1999) 0.92
A novel aminosaccharide compound blocks immune responses by Toll-like receptors and nucleotide-binding domain, leucine-rich repeat proteins. J Biol Chem (2010) 0.84
Membrane versus soluble isoforms of TNF-α exert opposing effects on tumor growth and survival of tumor-associated myeloid cells. Cancer Res (2013) 0.80
Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature (1995) 3.44
Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science (1999) 3.22
Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem (1999) 2.33
Domiciliary nebulisers in asthma: a district survey. Br Med J (Clin Res Ed) (1985) 1.65
Uncomplicated HL-A matched sibling bone marrow graft for combined immune deficiency. Br Med J (1972) 1.49
A biochemical and kinetic analysis of the interleukin-1 receptor. Evidence for differences in molecular properties of IL-1 receptors. J Biol Chem (1987) 1.47
Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J Immunol (1998) 1.43
Effect of interferon on the induction of human monocyte secretion of interleukin-1 activity. Immunology (1985) 1.40
Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets (2009) 1.32
Regulation of monocyte integrin expression by beta-family chemokines. J Immunol (1994) 1.30
Low intensity resistance exercise for breast cancer patients with arm lymphedema with or without compression sleeve. Lymphology (2005) 1.26
Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor. J Biol Chem (1990) 1.25
Modification of tumor necrosis factor-alpha (TNF-alpha) production by the Na(+)-dependent HCO3- cotransport in lipopolysaccharide-activated human monocytes. Immunopharmacology (1995) 1.11
Activation and distribution of inflammatory cells in the mouse uterus during the preimplantation period. J Immunol (1992) 1.08
Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. J Immunol (1999) 1.03
Identification of IL-1 receptors on human monocytes. J Immunol (1989) 1.02
Human monocyte production of interleukin-1: parameters of the induction of interleukin-1 secretion by lipopolysaccharides. J Leukoc Biol (1986) 1.00
Permuteins of interleukin 1 beta--a simplified approach for the construction of permutated proteins having new termini. Protein Eng (1992) 0.96
The Charing Cross Hospital Child Development Centre: a description of its work ad an evaluation of its first 385 patients. Child Care Health Dev (1978) 0.96
Biology of TACE inhibition. Ann Rheum Dis (2001) 0.93
Role of glucose in interleukin-1 beta production by lipopolysaccharide-activated human monocytes. J Cell Physiol (1993) 0.92
2'-substituted chalcone derivatives as inhibitors of interleukin-1 biosynthesis. J Med Chem (1993) 0.92
Scarring alopecia. Dermatol Clin (1987) 0.90
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem (2001) 0.89
Comparison of biological responses of human monocytes and THP-1 cells to chemokines of the intercrine-beta family. J Leukoc Biol (1994) 0.89
High-level expression in Escherichia coli of a soluble and fully active recombinant interleukin-1 beta. Mol Biol Med (1987) 0.89
Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha. Proc Natl Acad Sci U S A (2001) 0.88
Pigmented purpuric eruptions. Dermatol Clin (1985) 0.88
Aggrecanase. A target for the design of inhibitors of cartilage degradation. Ann N Y Acad Sci (1999) 0.88
Internalization and nuclear localization of interleukin 1 are not sufficient for function. Cell Growth Differ (1991) 0.85
A Case of Pulmonary Osteo-Arthropathy. Trans Am Climatol Assoc (1901) 0.84
Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. J Exp Med (1988) 0.84
Quantitation of related proteins by Western blot analysis. J Immunol Methods (1988) 0.83
The thyroid. Dermatol Clin (1989) 0.82
Escherichia coli: derived murine interleukin-1 beta with N-terminus partially N alpha-acetylated. Protein Expr Purif (1993) 0.81
Repigmentation of vitiliginous skin by cultured cells. Pigment Cell Res (1989) 0.81
Angiolymphoid hyperplasia with eosinophilia. A case report and review of the literature. Arch Otolaryngol Head Neck Surg (1988) 0.81
Muteins of human interleukin-1 that show enhanced bioactivities. FEBS Lett (1987) 0.80
Association of interleukin-1-induced, NF kappa B DNA-binding activity with collagenase gene expression in human gingival fibroblasts. Arch Oral Biol (1996) 0.80
Type I interleukin-1 receptors in the mouse brain-endocrine-immune axis labelled with [125I]recombinant human interleukin-1 receptor antagonist. J Neuroimmunol (1992) 0.80
The need for a do-not-resuscitate policy in a public city hospital. J Natl Med Assoc (1988) 0.79
Discrimination between nonmalignant and malignant cells by combinations of IFN-gamma and IFN-alpha/beta. J Biol Response Mod (1984) 0.79
Some Observations which Appear to Establish the Aërial Transportation of Malarial Germs. Trans Am Climatol Assoc (1895) 0.79
Species differences in [125I]interleukin-1 binding in brain, endocrine and immune tissues. Brain Res (1993) 0.79
Effect of antiinflammatory drugs on human interleukin-1-induced cartilage degradation. Agents Actions (1987) 0.78
The total chemical synthesis of monocyte chemotactic protein-1 (MCP-1). J Pept Sci (1997) 0.78
The immune response of allophenic mice to 2,4-dinitrophenyl (DNP)-bovine gamma globulin. I. Allotype analysis of anti-DNP antibody. J Exp Med (1978) 0.78
Characterization of murine IL-1 beta. Isolation, expression, and purification. J Immunol (1988) 0.77
Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production. Bioorg Med Chem Lett (1999) 0.77
Terphenyl cyclooxygenase-2 (COX-2) inhibitors: optimization of the central ring and o-biphenyl analogs. Bioorg Med Chem Lett (1999) 0.77
Human N-terminal analogs of interleukin 1 beta demonstrate altered binding and function in hematopoiesis. Exp Hematol (1990) 0.77
Selective non-peptide ligands for an accommodating peptide receptor. Imidazobenzodiazepines as potent cholecystokinin type B receptor antagonists. Bioorg Med Chem (1994) 0.76
A surgical treatment for vitiligo: autologous cultured-epithelial grafts. J Dermatol Surg Oncol (1989) 0.76
Macrocyclic amino carboxylates as selective MMP-8 inhibitors. J Med Chem (1998) 0.76
Coeliac syndrome. Proc R Soc Med (1968) 0.76
Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett (1998) 0.76
Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol (1986) 0.75
Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. J Med Chem (1994) 0.75
Necrotizing Enteritis Following Myomectomy. Proc R Soc Med (1965) 0.75
A Preliminary Report upon some Ambulatory Cases of Tuberculosis, Treated by Tuberculin. Trans Am Climatol Clin Assoc (1917) 0.75
Systemic interleukin I administration suppresses arachidonic acid-induced ear oedema in the mouse. Br J Dermatol (1989) 0.75
A Sketch of the Origin of Auscultation and Percussion and of the State of Clinical Medicine in the time of Auenbrugger and Laënnec. Trans Am Climatol Clin Assoc (1914) 0.75
A clinical trial of topical terbinafine (a new allylamine antifungal) in the treatment of tinea pedis. J Am Acad Dermatol (1990) 0.75
P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors. Bioorg Med Chem Lett (1999) 0.75
Phenylacetamides as selective alpha-1A adrenergic receptor antagonists. Bioorg Med Chem Lett (2000) 0.75
Fifty Cases of Tuberculosis, Mainly Gaseous and Glandular, Treated with Tuberculin Contrasted with Fifty Cases Treated without Tuberculin. Trans Am Climatol Clin Assoc (1918) 0.75
Studies in Deep Breathing. Trans Am Climatol Assoc (1903) 0.75
Effects of intracellular ions on interleukin-1 beta production by lipopolysaccharide-activated human monocytes. Am J Physiol (1992) 0.75
Genetic control of the immune response of mice to highly dinitrophenylated human gamma-globulin (DNP56HGG). J Immunol (1980) 0.75
Giant Mycobacterium fortuitum abscess associated with systemic lupus erythematosus. Arch Dermatol (1986) 0.75
Some Personal Observations upon the Effects of Changes of Climate upon Men and Animals. Trans Am Climatol Assoc (1897) 0.75
Kyanite-Andalusite Equilibrium from 700{degrees} to 800{degrees}C. Science (1966) 0.75
Heightened cutaneous reactions to mosquito bites in patients with acquired immunodeficiency syndrome receiving zidovudine. Arch Intern Med (1988) 0.75
Traumatic Ruptures of the Heart, with a Case. Trans Am Climatol Assoc (1899) 0.75
Hygiene in the Prophylaxis and Treatment of Consumption. Trans Am Climatol Assoc (1907) 0.75
Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus in a patient with lymphoma. J Am Acad Dermatol (1996) 0.75
Some of the Rules for the Treatment of Consumption laid down by Sydenham and his Successors. Trans Am Climatol Assoc (1911) 0.75
Cyclic imides as potent and selective alpha-1A adrenergic receptor antagonists. Bioorg Med Chem Lett (2001) 0.75
Kyanite-Sillimanite Equilibrium at 750{degrees}C. Science (1966) 0.75
Dampness as a Factor in Tuberculosis. Trans Am Climatol Assoc (1900) 0.75
Modulation of synovial fibroblast plasminogen activator and plasminogen activator inhibitor production by protein kinase C. Biochim Biophys Acta (1991) 0.75
Modulation of contact sensitivity in mice by interleukins. Acta Derm Venereol Suppl (Stockh) (1988) 0.75
A Case of Enlarged Thymus Gland: And Some Remarks on Status Lymphaticus. Trans Am Climatol Clin Assoc (1919) 0.75